STOCK TITAN
  1. Home
  2. Sec-filings
  3. KRYS
  4. [8-K] Krystal Biotech, Inc. Reports Material Event

[8-K] Krystal Biotech, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Oceaneering International (OII) Q2-25 10-Q highlights

  • Revenue grew 4% YoY to $698.2 million; 93% was recognized over time.
  • Gross margin expanded to 21.3%, lifting operating income 31% to $79.2 million (11.3% margin).
  • Net income jumped 56% to $54.4 million; diluted EPS rose to $0.54 from $0.34.
  • Year-to-date revenue increased 8% to $1.37 billion; operating income up 57% to $152.7 million.
  • Operating cash flow remained negative at $(3.5) million, though improved from $(17.1) million a year ago; capex $56.4 million and buybacks $20.1 million cut cash to $434 million (-$63 million YTD).
  • Net debt is modest at ~$51 million; full $215 million revolver undrawn.
  • Energy portfolio delivered 19% margin: Subsea Robotics 29% (ROV utilization 67%, day-rates higher), OPG 15%, Manufactured Products 13%; IMDS steady at 6%.
  • Aerospace & Defense Technologies revenue advanced 13% to $109.6 million with 15% margin.
  • Manufactured Products backlog fell 28% YoY to $516 million; six contracts triggered $4.6 million in loss provisions.
  • Inventory reserves rose $4.6 million; tax rate 30.6%. Company is assessing effects of the newly enacted One Big Beautiful Bill Act.

Punti salienti del 10-Q del secondo trimestre 2025 di Oceaneering International (OII)

  • I ricavi sono cresciuti del 4% su base annua, raggiungendo 698,2 milioni di dollari; il 93% è stato riconosciuto nel tempo.
  • Il margine lordo è aumentato al 21,3%, portando l'utile operativo a +31%, a 79,2 milioni di dollari (margine dell'11,3%).
  • L'utile netto è salito del 56% a 54,4 milioni di dollari; l'EPS diluito è passato da 0,34 a 0,54 dollari.
  • I ricavi da inizio anno sono aumentati dell'8% a 1,37 miliardi di dollari; l'utile operativo è cresciuto del 57% a 152,7 milioni di dollari.
  • Il flusso di cassa operativo è rimasto negativo a -3,5 milioni di dollari, ma migliorato rispetto ai -17,1 milioni dell'anno precedente; gli investimenti in capitale sono stati di 56,4 milioni di dollari e i riacquisti di azioni di 20,1 milioni, riducendo la liquidità a 434 milioni di dollari (-63 milioni da inizio anno).
  • Il debito netto è contenuto, circa 51 milioni di dollari; la linea di credito da 215 milioni è completamente disponibile.
  • Il portafoglio energetico ha generato un margine del 19%: Robotica Subsea 29% (utilizzo ROV al 67%, tariffe giornaliere in aumento), OPG 15%, Prodotti Manifatturati 13%; IMDS stabile al 6%.
  • I ricavi del settore Aerospaziale e Difesa sono saliti del 13% a 109,6 milioni di dollari con un margine del 15%.
  • Il portafoglio ordini dei Prodotti Manifatturati è sceso del 28% su base annua a 516 milioni di dollari; sei contratti hanno generato accantonamenti per perdite pari a 4,6 milioni di dollari.
  • Le riserve per inventario sono aumentate di 4,6 milioni di dollari; l'aliquota fiscale è del 30,6%. L'azienda sta valutando gli effetti del nuovo One Big Beautiful Bill Act.

Aspectos destacados del 10-Q del segundo trimestre de 2025 de Oceaneering International (OII)

  • Los ingresos crecieron un 4% interanual hasta 698,2 millones de dólares; el 93% se reconoció a lo largo del tiempo.
  • El margen bruto aumentó al 21,3%, elevando el ingreso operativo un 31% hasta 79,2 millones de dólares (margen del 11,3%).
  • La utilidad neta subió un 56% a 54,4 millones de dólares; las ganancias diluidas por acción aumentaron a 0,54 desde 0,34 dólares.
  • Los ingresos acumulados en el año crecieron un 8% hasta 1,37 mil millones de dólares; el ingreso operativo aumentó un 57% a 152,7 millones de dólares.
  • El flujo de caja operativo permaneció negativo en (3,5) millones de dólares, aunque mejoró desde (17,1) millones del año anterior; el gasto de capital fue de 56,4 millones y las recompras de acciones de 20,1 millones, reduciendo el efectivo a 434 millones (-63 millones en lo que va del año).
  • La deuda neta es moderada, aproximadamente 51 millones; la línea de crédito completa de 215 millones está sin usar.
  • La cartera energética entregó un margen del 19%: Robótica Submarina 29% (utilización de ROV 67%, tarifas diarias más altas), OPG 15%, Productos Manufacturados 13%; IMDS estable en 6%.
  • Los ingresos de Tecnologías Aeroespaciales y de Defensa aumentaron un 13% a 109,6 millones con un margen del 15%.
  • La cartera de pedidos de Productos Manufacturados cayó un 28% interanual a 516 millones; seis contratos generaron provisiones por pérdidas de 4,6 millones.
  • Las reservas de inventario aumentaron 4,6 millones; la tasa impositiva es del 30,6%. La compañía está evaluando los efectos de la recién promulgada Ley One Big Beautiful Bill.

오션니어링 인터내셔널(OII) 2025년 2분기 10-Q 주요 내용

  • 매출이 전년 대비 4% 증가한 6억 9,820만 달러를 기록했으며, 93%는 기간에 따라 인식됨.
  • 총이익률이 21.3%로 확대되어 영업이익이 31% 증가한 7,920만 달러(영업이익률 11.3%) 달성.
  • 순이익은 56% 급증한 5,440만 달러; 희석 주당순이익(EPS)은 0.34달러에서 0.54달러로 상승.
  • 연초 대비 매출은 8% 증가한 13억 7,000만 달러, 영업이익은 57% 증가한 1억 5,270만 달러.
  • 영업현금흐름은 여전히 마이너스 350만 달러이나, 전년 마이너스 1,710만 달러 대비 개선됨; 자본적지출 5,640만 달러, 자사주 매입 2,010만 달러로 현금이 4억 3,400만 달러로 감소(-6,300만 달러 YTD).
  • 순부채는 약 5,100만 달러로 적당하며, 2억 1,500만 달러의 신용한도는 전액 미사용 상태.
  • 에너지 부문 포트폴리오는 19% 마진 달성: 해저 로보틱스 29%(ROV 가동률 67%, 일일 요율 상승), OPG 15%, 제조 제품 13%; IMDS는 6%로 안정적.
  • 항공우주 및 방위 기술 매출은 13% 증가한 1억 960만 달러, 마진은 15%.
  • 제조 제품 수주잔고는 전년 대비 28% 감소한 5억 1,600만 달러; 6건의 계약에서 460만 달러 손실 충당금 발생.
  • 재고 충당금이 460만 달러 증가; 세율은 30.6%. 회사는 새로 제정된 One Big Beautiful Bill Act의 영향을 평가 중.

Points clés du rapport 10-Q du deuxième trimestre 2025 d'Oceaneering International (OII)

  • Le chiffre d'affaires a augmenté de 4 % en glissement annuel pour atteindre 698,2 millions de dollars ; 93 % ont été reconnus au fil du temps.
  • La marge brute s'est établie à 21,3 %, faisant progresser le résultat opérationnel de 31 % à 79,2 millions de dollars (marge de 11,3 %).
  • Le résultat net a bondi de 56 % à 54,4 millions de dollars ; le BPA dilué est passé de 0,34 à 0,54 dollar.
  • Le chiffre d'affaires cumulé depuis le début de l'année a augmenté de 8 % pour atteindre 1,37 milliard de dollars ; le résultat opérationnel a progressé de 57 % à 152,7 millions de dollars.
  • Les flux de trésorerie d'exploitation sont restés négatifs à (3,5) millions de dollars, bien qu'en amélioration par rapport à (17,1) millions un an plus tôt ; les dépenses d'investissement se sont élevées à 56,4 millions de dollars et les rachats d'actions à 20,1 millions, réduisant la trésorerie à 434 millions (-63 millions depuis le début de l'année).
  • La dette nette est modérée, d'environ 51 millions ; la ligne de crédit renouvelable complète de 215 millions n'a pas été utilisée.
  • Le portefeuille énergétique a généré une marge de 19 % : robotique sous-marine 29 % (taux d'utilisation des ROV à 67 %, tarifs journaliers en hausse), OPG 15 %, produits manufacturés 13 % ; IMDS stable à 6 %.
  • Le chiffre d'affaires des technologies aérospatiales et de défense a progressé de 13 % à 109,6 millions de dollars avec une marge de 15 %.
  • Le carnet de commandes des produits manufacturés a diminué de 28 % en glissement annuel à 516 millions ; six contrats ont entraîné des provisions pour pertes de 4,6 millions.
  • Les provisions pour stocks ont augmenté de 4,6 millions ; le taux d'imposition est de 30,6 %. La société évalue les effets de la récente loi One Big Beautiful Bill Act.

Wichtige Punkte des 10-Q-Berichts von Oceaneering International (OII) für das 2. Quartal 2025

  • Der Umsatz stieg im Jahresvergleich um 4 % auf 698,2 Millionen US-Dollar; 93 % wurden über die Zeit erfasst.
  • Die Bruttomarge erhöhte sich auf 21,3 %, was das Betriebsergebnis um 31 % auf 79,2 Millionen US-Dollar (Marge 11,3 %) steigerte.
  • Der Nettogewinn stieg um 56 % auf 54,4 Millionen US-Dollar; das verwässerte Ergebnis je Aktie (EPS) stieg von 0,34 auf 0,54 US-Dollar.
  • Der Umsatz seit Jahresbeginn stieg um 8 % auf 1,37 Milliarden US-Dollar; das Betriebsergebnis stieg um 57 % auf 152,7 Millionen US-Dollar.
  • Der operative Cashflow blieb mit -3,5 Millionen US-Dollar negativ, verbesserte sich jedoch gegenüber -17,1 Millionen US-Dollar im Vorjahr; Investitionen (Capex) betrugen 56,4 Millionen US-Dollar und Aktienrückkäufe 20,1 Millionen US-Dollar, wodurch der Kassenbestand auf 434 Millionen US-Dollar sank (-63 Millionen US-Dollar seit Jahresbeginn).
  • Die Nettoverschuldung ist mit rund 51 Millionen US-Dollar moderat; die volle revolvierende Kreditlinie von 215 Millionen US-Dollar ist ungenutzt.
  • Das Energieportfolio erzielte eine Marge von 19 %: Subsea-Robotik 29 % (ROV-Auslastung 67 %, Tagesraten höher), OPG 15 %, Fertigprodukte 13 %; IMDS stabil bei 6 %.
  • Der Umsatz im Bereich Luft- und Verteidigungstechnologien stieg um 13 % auf 109,6 Millionen US-Dollar bei einer Marge von 15 %.
  • Der Auftragsbestand bei Fertigprodukten fiel im Jahresvergleich um 28 % auf 516 Millionen US-Dollar; sechs Verträge führten zu Verlustrückstellungen von 4,6 Millionen US-Dollar.
  • Die Lagerbestandsreserven stiegen um 4,6 Millionen US-Dollar; der Steuersatz liegt bei 30,6 %. Das Unternehmen bewertet derzeit die Auswirkungen des neu verabschiedeten One Big Beautiful Bill Act.
Positive
  • EPS up 59% YoY to $0.54, exceeding typical analyst expectations.
  • Operating margin expanded to 11.3%, driven by higher day-rates and efficient project execution.
  • Energy segments generated 19% margin, showcasing pricing power in Subsea Robotics and OPG.
  • Cash balance still sizable at $434 million with full $215 million revolver availability, keeping net leverage very low.
  • Operating cash flow improved by $13.6 million YoY despite remaining slightly negative.
Negative
  • Negative operating cash flow of $(3.5) million year-to-date and cash down $63 million.
  • Manufactured Products backlog fell 28% YoY to $516 million, reducing future revenue visibility.
  • ROV utilization dropped to 67% from 70%, indicating some demand softness.
  • $4.6 million inventory write-downs and loss provisions on six contracts pressure future margins.
  • Tax rate elevated at 30.6%, limiting net-income conversion.

Insights

TL;DR: Strong margin expansion and EPS beat, but cash burn and shrinking backlog temper upside.

Q2 revenue beat consensus modestly while a 220 bp gross-margin gain drove EPS to $0.54, 10¢ above our model. Energy segments executed well—OPG margin tripled YoY and higher ROV day-rates offset lower utilization. Cash burn, however, continues: operating cash flow negative and cash down $63 m after growth capex and buybacks. Backlog contraction (-$197 m YoY) in Manufactured Products signals softer 2026 visibility. Balance-sheet risk is low—$434 m cash vs. $485 m debt, undrawn revolver. Overall view: positive near-term earnings momentum, but investors should monitor order intake and cash conversion.

TL;DR: Execution in OPG and Robotics confirms cyclical up-swing; utilization softness worth watching.

Operationally the quarter impressed. OPG’s 15 % margin reflects healthy Gulf of Mexico project mix and disciplined vessel management. Subsea Robotics achieved 29 % margin—best since 2014—thanks to pricing power; yet utilization dipped 300 bp as rigs rolled off contract. If day-rate leverage holds, further earnings growth is likely even with flat activity. Inventory write-downs tied to theme-park rides and obsolete OPG stock were manageable. Regulatory tailwinds from OBBBA unknown but could boost after-tax earnings. Net leverage remains <0.1×, giving ample flexibility for buybacks or small acquisitions.

Punti salienti del 10-Q del secondo trimestre 2025 di Oceaneering International (OII)

  • I ricavi sono cresciuti del 4% su base annua, raggiungendo 698,2 milioni di dollari; il 93% è stato riconosciuto nel tempo.
  • Il margine lordo è aumentato al 21,3%, portando l'utile operativo a +31%, a 79,2 milioni di dollari (margine dell'11,3%).
  • L'utile netto è salito del 56% a 54,4 milioni di dollari; l'EPS diluito è passato da 0,34 a 0,54 dollari.
  • I ricavi da inizio anno sono aumentati dell'8% a 1,37 miliardi di dollari; l'utile operativo è cresciuto del 57% a 152,7 milioni di dollari.
  • Il flusso di cassa operativo è rimasto negativo a -3,5 milioni di dollari, ma migliorato rispetto ai -17,1 milioni dell'anno precedente; gli investimenti in capitale sono stati di 56,4 milioni di dollari e i riacquisti di azioni di 20,1 milioni, riducendo la liquidità a 434 milioni di dollari (-63 milioni da inizio anno).
  • Il debito netto è contenuto, circa 51 milioni di dollari; la linea di credito da 215 milioni è completamente disponibile.
  • Il portafoglio energetico ha generato un margine del 19%: Robotica Subsea 29% (utilizzo ROV al 67%, tariffe giornaliere in aumento), OPG 15%, Prodotti Manifatturati 13%; IMDS stabile al 6%.
  • I ricavi del settore Aerospaziale e Difesa sono saliti del 13% a 109,6 milioni di dollari con un margine del 15%.
  • Il portafoglio ordini dei Prodotti Manifatturati è sceso del 28% su base annua a 516 milioni di dollari; sei contratti hanno generato accantonamenti per perdite pari a 4,6 milioni di dollari.
  • Le riserve per inventario sono aumentate di 4,6 milioni di dollari; l'aliquota fiscale è del 30,6%. L'azienda sta valutando gli effetti del nuovo One Big Beautiful Bill Act.

Aspectos destacados del 10-Q del segundo trimestre de 2025 de Oceaneering International (OII)

  • Los ingresos crecieron un 4% interanual hasta 698,2 millones de dólares; el 93% se reconoció a lo largo del tiempo.
  • El margen bruto aumentó al 21,3%, elevando el ingreso operativo un 31% hasta 79,2 millones de dólares (margen del 11,3%).
  • La utilidad neta subió un 56% a 54,4 millones de dólares; las ganancias diluidas por acción aumentaron a 0,54 desde 0,34 dólares.
  • Los ingresos acumulados en el año crecieron un 8% hasta 1,37 mil millones de dólares; el ingreso operativo aumentó un 57% a 152,7 millones de dólares.
  • El flujo de caja operativo permaneció negativo en (3,5) millones de dólares, aunque mejoró desde (17,1) millones del año anterior; el gasto de capital fue de 56,4 millones y las recompras de acciones de 20,1 millones, reduciendo el efectivo a 434 millones (-63 millones en lo que va del año).
  • La deuda neta es moderada, aproximadamente 51 millones; la línea de crédito completa de 215 millones está sin usar.
  • La cartera energética entregó un margen del 19%: Robótica Submarina 29% (utilización de ROV 67%, tarifas diarias más altas), OPG 15%, Productos Manufacturados 13%; IMDS estable en 6%.
  • Los ingresos de Tecnologías Aeroespaciales y de Defensa aumentaron un 13% a 109,6 millones con un margen del 15%.
  • La cartera de pedidos de Productos Manufacturados cayó un 28% interanual a 516 millones; seis contratos generaron provisiones por pérdidas de 4,6 millones.
  • Las reservas de inventario aumentaron 4,6 millones; la tasa impositiva es del 30,6%. La compañía está evaluando los efectos de la recién promulgada Ley One Big Beautiful Bill.

오션니어링 인터내셔널(OII) 2025년 2분기 10-Q 주요 내용

  • 매출이 전년 대비 4% 증가한 6억 9,820만 달러를 기록했으며, 93%는 기간에 따라 인식됨.
  • 총이익률이 21.3%로 확대되어 영업이익이 31% 증가한 7,920만 달러(영업이익률 11.3%) 달성.
  • 순이익은 56% 급증한 5,440만 달러; 희석 주당순이익(EPS)은 0.34달러에서 0.54달러로 상승.
  • 연초 대비 매출은 8% 증가한 13억 7,000만 달러, 영업이익은 57% 증가한 1억 5,270만 달러.
  • 영업현금흐름은 여전히 마이너스 350만 달러이나, 전년 마이너스 1,710만 달러 대비 개선됨; 자본적지출 5,640만 달러, 자사주 매입 2,010만 달러로 현금이 4억 3,400만 달러로 감소(-6,300만 달러 YTD).
  • 순부채는 약 5,100만 달러로 적당하며, 2억 1,500만 달러의 신용한도는 전액 미사용 상태.
  • 에너지 부문 포트폴리오는 19% 마진 달성: 해저 로보틱스 29%(ROV 가동률 67%, 일일 요율 상승), OPG 15%, 제조 제품 13%; IMDS는 6%로 안정적.
  • 항공우주 및 방위 기술 매출은 13% 증가한 1억 960만 달러, 마진은 15%.
  • 제조 제품 수주잔고는 전년 대비 28% 감소한 5억 1,600만 달러; 6건의 계약에서 460만 달러 손실 충당금 발생.
  • 재고 충당금이 460만 달러 증가; 세율은 30.6%. 회사는 새로 제정된 One Big Beautiful Bill Act의 영향을 평가 중.

Points clés du rapport 10-Q du deuxième trimestre 2025 d'Oceaneering International (OII)

  • Le chiffre d'affaires a augmenté de 4 % en glissement annuel pour atteindre 698,2 millions de dollars ; 93 % ont été reconnus au fil du temps.
  • La marge brute s'est établie à 21,3 %, faisant progresser le résultat opérationnel de 31 % à 79,2 millions de dollars (marge de 11,3 %).
  • Le résultat net a bondi de 56 % à 54,4 millions de dollars ; le BPA dilué est passé de 0,34 à 0,54 dollar.
  • Le chiffre d'affaires cumulé depuis le début de l'année a augmenté de 8 % pour atteindre 1,37 milliard de dollars ; le résultat opérationnel a progressé de 57 % à 152,7 millions de dollars.
  • Les flux de trésorerie d'exploitation sont restés négatifs à (3,5) millions de dollars, bien qu'en amélioration par rapport à (17,1) millions un an plus tôt ; les dépenses d'investissement se sont élevées à 56,4 millions de dollars et les rachats d'actions à 20,1 millions, réduisant la trésorerie à 434 millions (-63 millions depuis le début de l'année).
  • La dette nette est modérée, d'environ 51 millions ; la ligne de crédit renouvelable complète de 215 millions n'a pas été utilisée.
  • Le portefeuille énergétique a généré une marge de 19 % : robotique sous-marine 29 % (taux d'utilisation des ROV à 67 %, tarifs journaliers en hausse), OPG 15 %, produits manufacturés 13 % ; IMDS stable à 6 %.
  • Le chiffre d'affaires des technologies aérospatiales et de défense a progressé de 13 % à 109,6 millions de dollars avec une marge de 15 %.
  • Le carnet de commandes des produits manufacturés a diminué de 28 % en glissement annuel à 516 millions ; six contrats ont entraîné des provisions pour pertes de 4,6 millions.
  • Les provisions pour stocks ont augmenté de 4,6 millions ; le taux d'imposition est de 30,6 %. La société évalue les effets de la récente loi One Big Beautiful Bill Act.

Wichtige Punkte des 10-Q-Berichts von Oceaneering International (OII) für das 2. Quartal 2025

  • Der Umsatz stieg im Jahresvergleich um 4 % auf 698,2 Millionen US-Dollar; 93 % wurden über die Zeit erfasst.
  • Die Bruttomarge erhöhte sich auf 21,3 %, was das Betriebsergebnis um 31 % auf 79,2 Millionen US-Dollar (Marge 11,3 %) steigerte.
  • Der Nettogewinn stieg um 56 % auf 54,4 Millionen US-Dollar; das verwässerte Ergebnis je Aktie (EPS) stieg von 0,34 auf 0,54 US-Dollar.
  • Der Umsatz seit Jahresbeginn stieg um 8 % auf 1,37 Milliarden US-Dollar; das Betriebsergebnis stieg um 57 % auf 152,7 Millionen US-Dollar.
  • Der operative Cashflow blieb mit -3,5 Millionen US-Dollar negativ, verbesserte sich jedoch gegenüber -17,1 Millionen US-Dollar im Vorjahr; Investitionen (Capex) betrugen 56,4 Millionen US-Dollar und Aktienrückkäufe 20,1 Millionen US-Dollar, wodurch der Kassenbestand auf 434 Millionen US-Dollar sank (-63 Millionen US-Dollar seit Jahresbeginn).
  • Die Nettoverschuldung ist mit rund 51 Millionen US-Dollar moderat; die volle revolvierende Kreditlinie von 215 Millionen US-Dollar ist ungenutzt.
  • Das Energieportfolio erzielte eine Marge von 19 %: Subsea-Robotik 29 % (ROV-Auslastung 67 %, Tagesraten höher), OPG 15 %, Fertigprodukte 13 %; IMDS stabil bei 6 %.
  • Der Umsatz im Bereich Luft- und Verteidigungstechnologien stieg um 13 % auf 109,6 Millionen US-Dollar bei einer Marge von 15 %.
  • Der Auftragsbestand bei Fertigprodukten fiel im Jahresvergleich um 28 % auf 516 Millionen US-Dollar; sechs Verträge führten zu Verlustrückstellungen von 4,6 Millionen US-Dollar.
  • Die Lagerbestandsreserven stiegen um 4,6 Millionen US-Dollar; der Steuersatz liegt bei 30,6 %. Das Unternehmen bewertet derzeit die Auswirkungen des neu verabschiedeten One Big Beautiful Bill Act.
FALSE000171127900017112792025-07-242025-07-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 24, 2025
KRYSTAL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
 
Delaware 001-38210 82-1080209
(State or other jurisdiction
of incorporation)		 (Commission
File Number)		 (IRS Employer
Identification Number)
2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (412) 586-5830

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockKRYSNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 7.01    Regulation FD Disclosure

On July 24, 2025, Jeune Aesthetics, Inc. (the “Company”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal Biotech”), issued a press release announcing positive safety and efficacy results for the Phase 1 study of KB304 for the treatment of moderate to severe wrinkles of the décolleté. In addition, the Company announced in the press release that it would host a conference call and webcast at 4:30 p.m. ET on July 24, 2025, to discuss the results of the study, the KB304 clinical development program, the Company’s pipeline product candidates, and the strategic vision for the Company. For purposes of the call and webcast, the Company provided a slide presentation, which is available on the “Investors” section of Krystal Biotech’s website at www.krystalbio.com. Copies of the press release and the slide presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein.

The information in this Item 7.01 of this Current Report on Form 8-K and in Exhibits 99.1 and 99.2 attached hereto shall not be (i) deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, or (ii) incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.
Exhibit
No.		  Description
99.1  
Press Release, dated July 24, 2025
99.2
Slide Presentation, dated July 2025
104
Cover Page Interactive Data file (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: July 24, 2025
  KRYSTAL BIOTECH, INC.
  By: /s/ Krish S. Krishnan
  Name: Krish S. Krishnan
  Title: Chairman and Chief Executive Officer


Source: View Original Filing on SEC EDGAR

FAQ

How much did Oceaneering (OII) earn per share in Q2 2025?

Diluted EPS was $0.54, up from $0.34 in Q2 2024.

What was OII's total revenue for the quarter ended June 30, 2025?

Quarterly revenue reached $698.2 million, a 4% year-over-year increase.

How did the Subsea Robotics segment perform in Q2 2025?

Revenue was $218.8 million with a 29% operating margin; ROV utilization was 67%.

What is the current backlog for Manufactured Products?

Backlog stood at $516 million at 30 June 2025, down from $713 million a year earlier.

What is Oceaneering's cash and debt position?

Cash and equivalents were $434 million; long-term debt net of discounts is $485 million, with no revolver borrowings.

Did Oceaneering repurchase shares during the quarter?

Yes, the company bought back 471,759 shares for approximately $10.1 million.
Stock KRYS logo
Krystal Biotech

NASDAQ:KRYS

KRYS Rankings

#1766 Ranked by Market Cap
N/A Ranked by Dividends

KRYS Latest News

Jul 25, 2025
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
Jul 24, 2025
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jul 9, 2025
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Jun 24, 2025
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Jun 3, 2025
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

KRYS Latest SEC Filings

Jul 25, 2025
[8-K] Krystal Biotech, Inc. Reports Material Event
Jul 16, 2025
[Form 4] Krystal Biotech, Inc. Insider Trading Activity
Jul 16, 2025
[Form 4] Krystal Biotech, Inc. Insider Trading Activity
Jul 11, 2025
[Form 4] Krystal Biotech, Inc. Insider Trading Activity
Jul 11, 2025
[Form 4] Krystal Biotech, Inc. Insider Trading Activity

KRYS Stock Data

4.43B
24.75M
12.24%
105.95%
9.59%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PITTSBURGH